Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521414 | 1.00 | HTR2B (0.38) | HTR2BPRMT5WDR77ADORA3ADORA2A | |
| SCHEMBL22521487 | 1.00 | HTR2B (0.38) | HTR2BPRMT5WDR77ADORA3ADORA2A | |
| SCHEMBL23430009 | 1.00 | HTR2B (0.38) | HTR2BPRMT5WDR77ADORA3ADORA2A | |
| SCHEMBL22509807 | 0.90 | PRMT5 (0.35) | HTR2BPRMT5WDR77HRH2HTR5A | |
| SCHEMBL23429766 | 0.85 | HRH2 (0.34) | PRMT5WDR77HRH2HTR5A | |
| SCHEMBL21130304 | 0.84 | PRMT5 (0.37) | PRMT5WDR77HRH2HTR5A | |
| SCHEMBL22787756 | 0.84 | PRMT5 (0.35) | PRMT5WDR77HRH2HTR5A | |
| SCHEMBL23405208 | 0.82 | ADORA3 (0.33) | HTR2BADORA3ADORA2AHRH2HTR5A | |
| SCHEMBL23430004 | 0.82 | ADORA3 (0.33) | HTR2BADORA3ADORA2AHRH2HTR5A | |
| SCHEMBL21682243 | 0.82 | PRMT5 (0.40) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026094-B | PRMT5 inhibitors | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3980417-B1 | PRMT5 INHIBITORS | LUPIN LTD (IN) | 2023-09-27 | — | — | EP | disclosed |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-08-25 | — | — | US | disclosed |
| EP-3980417-A1 | PRMT5 INHIBITORS | Lupin Limited (IN) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HTR2B 4716/4885PRMT5 1/4885WDR77 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.